Dr. Margol is currently an attending pediatric neuro-oncologist, Director of the Brain Tumor Center, Director of the Neuro-Oncology Program and Director of the Neuro-Oncology Fellowship Program at

Children’s Hospital Los Angeles and Associate Professor of Clinical Pediatrics at the Keck School of Medicine.

Her clinical research interests are focused on infant embryonal central nervous system tumors. She co-leads the Atypical Teratoid Rhabdoid Tumor (ATRT) Working Group for the Pacific Pediatric Neuro-Oncology Consortium (PNOC) and is working to develop a comprehensive registry to establish an external control cohort for patients with this rare tumor. She and others in the ATRT PNOC Working Group are currently developing an innovative and adaptive clinical trial for children with relapsed disease.

ATRT Registry and New Clinical Trial Opening Soon

Sabine Mueller, MD, Ph.D., MAS is the Co-Founder and Project Lead of PNOC and Professor of Neurology, Neurosurgery and Pediatrics at University of California, San Francisco (UCSF) and Professor in the Department of Pediatrics of the University of Zurich, Switzerland. She is a board certified pediatric neuro-oncologist who specializes in the care of children and young adults with brain tumors. Prof. Mueller leads the pediatric brain tumor program at UCSF and serves as one of the leads of the pediatric malignancy program of the UCSF Helen Diller Comprehensive Cancer Center. Prior to completing medical school, she served as a scientist, director of genomics, and project leader for the brain tumor program at AGY Therapeutics, a biotechnology company in South San Francisco. Prof. Mueller earned her PhD and MD degrees from the University of Hamburg, Germany, and furthered her medical training at Harvard University and UCSF. She is board-certified in pediatrics, neurology with focus on child neurology, and neuro-oncology. In her research, Prof. Mueller focuses on developing new therapeutic approaches for children with brain tumors with a specific interest in diffuse midline glioma, as well as improving long-term cognitive outcomes.

She currently leads PNOC – an international clinical trial consortium with 22 sites in the US as well as sites in Switzerland, Netherlands, Israel, Australia, Egypt and India - and serves as the founder and Medical Lead of the Diffuse Midline Glioma center in Zurich, Switzerland. Recently, Dr. Mueller also joined the Childhood Brain Tumor Network as the executive co-chair and is an affiliated group leader at the Princess Maxima Center in the Netherlands. She has received multiple grants, including funding from the Department of Defense and the National Cancer Institute.

PI of Clinical Trial:  

• PNOC025: Magrolimab (NCT05169944)

Dr. Alyssa Reddy is a pediatric neurologist and neuro-oncologist with expertise in treating children who have tumors of the central nervous system. She has more than 25 years of experience in diagnosing and managing pediatric nervous system tumors.  Dr. Reddy aims to provide patients with compassionate care as well as access to cutting-edge treatment. Her research has focused on improving long-term survival and quality of life for children with brain tumors. She believes these goals are best accomplished through a collaborative approach from a diverse team of scientists and health care providers with the ability to offer new therapies through clinical trials.

Dr. Reddy led the first prospective cooperative group clinical trial specifically designed to treat ATRT. The study, Children’s Oncology Group, ACNS0333, demonstrated improved survival for patients with ATRT treated with intensive chemotherapy and focal radiation. Although outcomes have improved for children with ATRT, much work remains to be done to improve outcomes for all patients.

Dr. Reddy is co-chair of the PNOC ATRT Working Group and ATRT Registry Study.

Investigator of Clinical Trial:  Nivolumab-Ipilimumab (NCT04416568)

I am a pediatric neuro-oncologist with research interests in Phase I and Phase II clinical trials for children and young adults with primary brain and spinal cord tumors. I am also site investigator for Stanford Children's many neuro-oncology trials. Our institution is actively involved in the Pediatric Brain Tumor Consortium (PBTC), Children’s Brain Tumor Network (CBTN), Children's Oncology Group (COG), and the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC). As a part of these collaborations, we can be a part of the development of future therapies and bring options to our patients in hopes for a cure.